Bionano Genomics Inc. [BNGO] Stock trading around $1.37 per share: What’s Next?



Bionano Genomics Inc. [NASDAQ: BNGO] plunged by -$0.19 during the normal trading session on Monday and reaching a high of $1.51 during the day while it closed the day at $1.37. The company report on May 5, 2022 that Bionano Genomics Reports First Quarter 2022 Financial Results and Highlights Recent Business Progress.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


– 80% year-over-year revenue growth in Q1 2022.

Bionano Genomics Inc. stock has also loss -20.81% of its value over the past 7 days. However, BNGO stock has declined by -37.73% in the 3 months of the year. Over the past six months meanwhile, it has lost -75.18% and lost -54.18% year-on date.

The market cap for BNGO stock reached $427.07 million, with 311.73 million shares outstanding and 283.17 million shares in the current float. Compared to the average trading volume of 7.25M shares, BNGO reached a trading volume of 8527638 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Bionano Genomics Inc. [BNGO]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BNGO shares is $8.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BNGO stock is a recommendation set at 1.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

BTIG Research have made an estimate for Bionano Genomics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 16, 2021. While these analysts kept the previous recommendation, Ladenburg Thalmann raised their target price to Buy. The new note on the price target was released on September 24, 2020, representing the official price target for Bionano Genomics Inc. stock. Previously, the target price had yet another raise to $1.50, while Oppenheimer analysts kept a Outperform rating on BNGO stock.

The Average True Range (ATR) for Bionano Genomics Inc. is set at 0.18, with the Price to Sales ratio for BNGO stock in the period of the last 12 months amounting to 23.73. The Price to Book ratio for the last quarter was 1.05, with the Price to Cash per share for the same quarter was set at 0.69.

BNGO stock trade performance evaluation

Bionano Genomics Inc. [BNGO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -20.81. With this latest performance, BNGO shares dropped by -40.95% in over the last four-week period, additionally sinking by -75.18% over the last 6 months – not to mention a drop of -72.65% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BNGO stock in for the last two-week period is set at 29.88, with the RSI for the last a single of trading hit 25.18, and the three-weeks RSI is set at 33.64 for Bionano Genomics Inc. [BNGO]. The present Moving Average for the last 50 days of trading for this stock 2.0517, while it was recorded at 1.6460 for the last single week of trading, and 3.7433 for the last 200 days.

Bionano Genomics Inc. [BNGO]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Bionano Genomics Inc. [BNGO] shares currently have an operating margin of -428.79 and a Gross Margin at +4.47. Bionano Genomics Inc.’s Net Margin is presently recorded at -402.84.

Return on Equity for this stock declined to -38.92, with Return on Assets sitting at -33.11.

Bionano Genomics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.10 and a Current Ratio set at 13.00.

Bionano Genomics Inc. [BNGO]: Insider Ownership positions

There are presently around $118 million, or 27.10% of BNGO stock, in the hands of institutional investors. The top three institutional holders of BNGO stocks are: BLACKROCK INC. with ownership of 18,660,129, which is approximately 2.752% of the company’s market cap and around 2.00% of the total institutional ownership; VANGUARD GROUP INC, holding 14,825,634 shares of the stock with an approximate value of $23.13 million in BNGO stocks shares; and STATE STREET CORP, currently with $11.23 million in BNGO stock with ownership of nearly -4.307% of the company’s market capitalization.

Positions in Bionano Genomics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 87 institutional holders increased their position in Bionano Genomics Inc. [NASDAQ:BNGO] by around 10,305,421 shares. Additionally, 64 investors decreased positions by around 5,476,130 shares, while 36 investors held positions by with 59,882,430 shares. The mentioned changes placed institutional holdings at 75,663,981 shares, according to the latest SEC report filing. BNGO stock had 24 new institutional investments in for a total of 1,042,161 shares, while 30 institutional investors sold positions of 2,421,403 shares during the same period.